Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers

作者：Patricia J. Keller, Elizabeth J. Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Nico Cantone, Rosana Meyer, Jennifer A. Mertz, Victor Gehling, Jike Cui, Jacob I. Stuckey, Avinash Khanna, Feng Zhao, Zehua Chen, Ziyang Yu, Richard Cummings, Mohammed Taimi, Nehal J. Lakhani, Drew Rasco, Martin Gutierrez, Linda Duska, Michael Devitt, Ronda Rippley, Julian Levell, Jennifer Truong, Jing Wang, Kaiming Sun, Patrick Trojer · 年份：2026 · DOI：10.1158/0008-5472.32705707 · 研究领域：Chromatin Remodeling and Cancer、Retinoids in leukemia and cellular processes、Neuroblastoma Research and Treatments

<p>Tulmimetostat treatment results in greater PRC2 target gene expression induction in phenotypically sensitive ARID1A LOF cell lines</p>